Clinical validation of a public health policy-making platform for hearing loss (EVOTION): protocol for a big data study by Dritsakis, G et al.
 1Dritsakis G, et al. BMJ Open 2018;8:e020978. doi:10.1136/bmjopen-2017-020978
Open Access 
Clinical validation of a public health 
policy-making platform for hearing loss 
(EVOTION): protocol for a big 
data study
Giorgos Dritsakis,1,2 Dimitris Kikidis,3 Nina Koloutsou,4 Louisa Murdin,4 
Athanasios Bibas,3 Katherine Ploumidou,5 Ariane Laplante-Lévesque,6 
Niels Henrik Pontoppidan,6 Doris-Eva Bamiou1,2,7
To cite: Dritsakis G, Kikidis D, 
Koloutsou N, et al.  Clinical 
validation of a public health 
policy-making platform for 
hearing loss (EVOTION): protocol 
for a big data study. BMJ Open 
2018;8:e020978. doi:10.1136/
bmjopen-2017-020978
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
020978).
Received 5 December 2017
Accepted 8 December 2017
1Ear Institute, University College 
London, London, UK
2Royal National Throat Nose & 
Ear Hospital, London, UK
31st Department of 
Otolaryngology, National and 
Kapodistrian University of 
Athens, Hippocrateion Hospital, 
Athens, Greece
4Guy’s and St Thomas’ NHS 
Foundation Trust, London, UK
5Athens Medical Center, Athens, 
Greece
6Eriksholm Research Centre, 
Elsinore, Denmark
7NIHR University College London 
Hospitals Biomedical Research 
Centre, London, UK
Correspondence to
Professor Doris-Eva Bamiou;  
 d. bamiou@ ucl. ac. uk
Protocol
AbstrACt
Introduction The holistic management of hearing 
loss (HL) requires an understanding of factors that 
predict hearing aid (HA) use and benefit beyond the 
acoustics of listening environments. Although several 
predictors have been identified, no study has explored 
the role of audiological, cognitive, behavioural and 
physiological data nor has any study collected real-time 
HA data. This study will collect ‘big data’, including 
retrospective HA logging data, prospective clinical data 
and real-time data via smart HAs, a mobile application 
and biosensors. The main objective is to enable the 
validation of the EVOTION platform as a public health 
policy-making tool for HL.
Methods and analysis This will be a big data 
international multicentre study consisting of 
retrospective and prospective data collection. Existing 
data from approximately 35 000 HA users will be 
extracted from clinical repositories in the UK and 
Denmark. For the prospective data collection, 1260 HA 
candidates will be recruited across four clinics in the 
UK and Greece. Participants will complete a battery 
of audiological and other assessments (measures of 
patient-reported HA benefit, mood, cognition, quality 
of life). Patients will be offered smart HAs and a 
mobile phone application and a subset will also be 
given wearable biosensors, to enable the collection of 
dynamic real-life HA usage data. Big data analytics will 
be used to detect correlations between contextualised 
HA usage and effectiveness, and different factors and 
comorbidities affecting HL, with a view to informing 
public health decision-making.
Ethics and dissemination Ethical approval was 
received from the London South East Research Ethics 
Committee (17/LO/0789), the Hippokrateion Hospital 
Ethics Committee (1847) and the Athens Medical 
Center’s Ethics Committee (KM140670). Results will be 
disseminated through national and international events 
in Greece and the UK, scientific journals, newsletters, 
magazines and social media. Target audiences include 
HA users, clinicians, policy-makers and the general 
public.
trial registration number NCT03316287; Pre-results.
IntroduCtIon   
Hearing loss (HL) affects approximately 
one-third of people over the age of 65 and 
over 5% of the world’s population.1 It is 
the fifth leading cause of years lived with 
disability, higher than diabetes and visual 
impairment.2 HL prevalence is on the rise 
worldwide, primarily due to increased noise 
exposure and increase in the ageing popula-
tion, with the number of people with disabling 
HL (ie, pure tone audiogram >40 dB) world-
wide rising from 278 million in 2005 to more 
than 360 million in 2012.1 In the UK, the 
percentage of people suffering from HL 
(ie, pure tone audiometry (PTA) >25 dB) is 
expected to exceed 20% of the population 
by 2031.3 Addressing the needs of a growing 
ageing population, including hearing-related 
needs, requires careful resource allocation in 
health and social care.2 HL has recently been 
associated with a higher risk of dementia, 
mental illness and depression and an adverse 
overall effect on general health.4 It also has 
strengths and limitations of this study
 ► This is the first big data study collecting both 
retrospective, and prospective real-time, hearing aid 
use and context-related, behavioural and 
physiological data from hearing aid users.
 ► The data collected will validate a prototype public 
health policy-making platform to inform decisions 
regarding hearing loss management.
 ► The study will deploy a mobile application on 
a smartphone issued to the hearing  aid users 
that includes self-administered speech in noise 
testing, cognitive testing and auditory training, and 
biosensors.
 ► There is a risk that not all patients will engage with 
the equipment used in this study, that is, smart 
hearing aids, smartphones and biosensors.
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important economic consequences, including work 
discrimination, reduced productivity, unemployment, 
early retirement and loss of income.5 6 The treatment of 
HL also has a significant cost estimated to be €213 billion 
per year in the European Union.7 
Currently, the leading management strategy for the vast 
majority of patients with HL is the provision of hearing 
aids (HAs). There is evidence that HAs are effective at 
improving general health-related quality of life (HRQOL), 
hearing-specific QOL associated with participation in 
daily activities and listening ability.8 However, HA users 
still face significant challenges, such as listening in noisy 
environments, poor sound quality and difficulty to select 
among predefined programmes and settings.9 10 As a 
result, many adults, especially elderly, do not accustom to 
their HAs and do not use them.10 Moreover, it is unclear 
whether HAs are equally effective for adults with different 
degrees of severity of HL.11 Ideally, HA fitting should: 
(1) take into account a range of personal and real-life 
behavioural, physiological and other audiological factors; 
(2) adapt to the challenging and changing situations for 
individual HA users on a continuous basis and (3) be 
supported by individualised rehabilitation treatments 
such as auditory training.12 However, linking such infor-
mation to appropriate management strategies requires a 
better understanding of the role of several factors beyond 
the acoustic characteristics of the various environments 
in which HAs are worn. These factors include the activ-
ities of the HA user in different environments as well as 
other physiological, cognitive and medical conditions on 
HA use and benefit.
Several studies have examined mostly demographic 
and self-reported factors that predict HA uptake and 
outcomes. The most robust predictors are self-reported 
hearing disability, age and degree of HL.13–16 HA users 
tend to overestimate their HA usage, as they report using 
their HAs more than what is measured by automatic HA 
logs.17 18 It is thus important to use objective data logging 
of HA use for accurate information. This automatic 
logging has been used in both adults and children with 
hearing impairments to explore how often, for how long 
and in which situations HAs are and are not used, as well 
as the factors that are associated with higher usage.17 19 
Laplante-Lévesque et al18 showed that these patterns of 
HA usage are at least as important in predicting usage as 
the duration of HA use. A recent retrospective data-log-
ging study found no statistical difference in HA use 
between patients with mild and moderate HL with impli-
cations for the prescription of HAs for milder degrees of 
HL.20 However, to the knowledge of the authors, no study 
to date has looked at associations between audiological, 
cognitive, behavioural and physiological data and HA 
use and benefit, nor has any study collected real-time HA 
data.
The research project ‘EVidence-based management 
of hearing impairments: public health pOlicy making 
based on fusing big data analytics and simulaTION’ 
(EVOTION; http://www. h2020evotion. eu) aims to 
build the evidence base for the formulation of public 
health policies related to the prevention, early diag-
nosis, long-term treatment and rehabilitation of HL, 
as well as to the detection and prevention of cognitive 
decline and the socioeconomic inclusion of individuals 
with HL. Its ultimate objective is to enable and support 
a more holistic management of HL at the population 
level.21 To this end, the EVOTION project is devel-
oping public health policy decision models (PHPDMs) 
using a combination of factors potentially affecting the 
effectiveness of HL treatments and ways in which they 
can inform public health policy decisions.22 PHPDMs 
define, analyse and address a wide range of public 
health issues with the aim to provide different stake-
holders (eg, ministries, regulatory bodies, non-govern-
mental organisations) with tools for HL-related policy 
formulation. In addition to these models, EVOTION 
is developing a public health policy-making platform 
(hereafter ‘the EVOTION platform’) including compo-
nents enabling the static and real-time feeding of data 
into a data repository.23 The present clinical study, 
which is conducted as part of the EVOTION project, 
will collect a large set of heterogeneous data including 
retrospective HA logging data, prospective clinical data 
and real-time data via smart HAs, a mobile application 
with tests and auditory training and biosensors.
The primary objective of the clinical study is to feed 
these data into the EVOTION data repository to enable 
the validation of the EVOTION model and platform as a 
public health policy-making tool.
Secondary objectives are to:
1. identify predictors of HA use and outcome;
2. identify predictors of temporary or permanent thresh-
old shift following noise exposure in HA users;
3. identify predictors of cognitive decline;
4. investigate benefits of self-management of HA set-
tings;




This big data study consists of two parts.
Part 1: Retrospective data collection: Existing data (anony-
mised and in grouped format) will be collected and anal-
ysed. These data will include demographics, HL levels, 
cause and duration of HL, medical history and HA usage 
data.
Part 2: Prospective data collection: It will take place within 
the National Health System (NHS) of the UK and Greece, 
and within the private sector in Greece. However, while 
in the UK there is a standard HA fitting pathway nation-
wide, there is no such pathway in Greece. Thus, in the 
UK HA candidates will attend the routine clinical NHS 
HA fitting pathway but will be fitted with EVOTION smart 
HAs instead of the standard NHS HAs. In Greece, a dedi-
cated flow chart will be followed for the HA fitting for the 
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study purposes. In both countries, patients will undergo a 
battery of audiological and other assessments (including 
measures of patient-reported HA benefit, mood, cogni-
tion, QOL; see the Prospective data collection: EVOTION 
HA fitting pathway section). Study participants will be 
issued with a mobile phone application in addition to the 
HA and a subset with wearable biosensors, to enable the 
collection of dynamic real-life HA usage data in different 
environmental and situational contexts.
The choice of the prospective and retrospective data 
to be collected was based on factors identified from the 
medical literature that are potentially associated with 
HA usage and benefits. The aim of the clinical study is 
to collect information that will help profile each patient 
in sufficient detail to support optimal HA fitting and 
evidence-based policy-making for HL. See table 1 for a 
full list of the retrospective and prospective data to be 




Retrospective data from approximately 35 000 HA users will 
be extracted from existing clinical repositories held in the 
UK (University College London Hospital and Guy’s and St 
Thomas’ NHS Foundation Trust through the NHS Audit-
base) and Denmark (Oticon A/S).
Prospective study
A total of 1260 HA users will be recruited over 12 months 
in the UK and Greece across the following clinics:
Royal National Throat, Nose and Ear Hospital, Lon-
don, UK (380 patients)
Guy’s and St Thomas’ NHS Foundation Trust, Lon-
don, UK (380 patients)
Hippokrateion Hospital, University of Athens, Ath-
ens, Greece (300 patients)
Athens Medical Center, Athens, Greece (200 pa-
tients).




age ≥18 years old;
basic understanding of oral and written English/
Greek to complete the assessments (as judged by the 
treating audiologist);
mild to severe (ie, an average of 20–95 dB HL) unilat-
eral or bilateral sensorineural HL.24
Exclusion criteria
dementia indicated by the Montreal Cognitive Assess-
ment (MoCA) score <2325;
not willing or able to use their HAs for at least 2 hours 
daily on average;
not willing or able to use a smartphone.
recruitment
Participant identification
In the UK, participants will be recruited through the 
standard NHS HA fitting pathway. These will be patients 
referred for a HA fitting to the Hearing Aid Centre of 
the Royal National Throat, Nose and Ear Hospital or 
to the Audiology Department of Guy’s and St Thomas’ 
NHS Foundation Trust. In Greece, participants will be 
recruited from the NHS Ear, Nose and Throat outpatient 
clinics and the specialist Neurotology Clinic of the first 
Otolaryngology Department at the University of Athens 
and from the private sector department of Audiology, 
Otology and Neurotology of Athens Medical Centre.
For the above clinics, recruitment will be conducted 
through one of the following routes:
 ► Referral to a HA centre by primary/secondary/
tertiary care professionals with preliminary assess-
ment including PTA (UK only).
 ► Known HA users who require refit or upgrade of their 
HAs due to either obsolete technology or a change in 
audiological status (UK only).
 ► Self-referral/external referral. These patients will 
require full assessment at first visit including PTA and 
they may or may not go on to require HA fitting.
 ► Patients who have already attended the clinic and 
have been referred for HA fitting but have not been 
fitted for various reasons (personal choice, postponed 
appointment, financial reasons).
Consent
Potential participants will be primarily identified at the 
point of referral or booking. A member of the clinical 
(in cases where EVOTION researchers are not part of the 
routine clinical team) or research team will contact them 
prior to their clinical appointment and inform them of 
the opportunity to participate in the study through a 
patient information sheet and invitation letter at least 
48 hours prior to their appointment. Those willing to 
participate will be provisionally offered an EVOTION 
appointment (visit 1). Eligibility will be confirmed at visit 
1 after further clinical assessment. If the patient is suit-
able, they will have the opportunity to discuss the purpose 
and nature of the study, benefits and risks with a member 
of the research team and ask questions and will then be 
asked to complete and sign a consent form.
Prospective data collection: EVotIon hA fitting pathway
Visit 1: assessment
Individuals who have completed the consent form will 
be asked to complete their standard clinical assessments 
along with additional research data collection.
Standard prefit assessments include:
 ► Medical and audiological history: Short clinical inter-
view regarding clinical, medical and occupational 
history (eg, marital status, history of noise exposure, 
comorbidities) based on the relevant fields of the NHS 
Auditbase platform in the UK or equivalent questions 
in Greece.
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Table 1 Full list of data to be collected in the EVOTION clinical study
Generic data type Specific data type
Means of capture
Retrospective ProspectiveHA Sensor Mobile Clinic
HA logging Periods of HA usage X X X
Use and adjustment of HA controls X X
TTS episode 
related
Predicted TTS values due to noise exposure 
and time required for recovery
X X X
Time of occurrence and severity of actual 
TTS episodes
X X X X X
Self-administered PTA at 4 kHz X X
Audiological PTA in quiet X X X
Speech in Noise X X
Reaction time (in Speech in Noise and Digit 
Span tests)
X X X X
Satisfaction with HA usage X X X
Physiological Heart rate X X
Respiratory rate X X
Pulse X X
Cognitive Cognitive assessment X X
Digit recall test for auditory working memory X X




Diabetes X X X
Obesity X X X
Family history of HL X X X
History of medications X X X
Duration of HL X X X
Cause of HL X X X
Behavioural and 
lifestyle
Watching television X X X
Participating in conversations and meetings X X X
Rating of HA ease or difficulty to use X X
Socioeconomic status X X
Personal Education level X X X
Presence of significant others X X X
Age X X X
Gender X X X
Personal carer X X X
Occupational Employment history and current status 
(including noise exposure)
X X X
Environmental Location X X X
Noise type, frequency spectrum and level X X
Outdoor activities (eg, conversations) X X X
How these data will be collected (ie, automatically logged on the HA, via the wearable biosensor, the mobile phone 
application or at the clinic) and whether they will be collected at the retrospective (part 1) or the prospective (part 2) study is 
specified. Also see the ‘Study design’, ‘Prospective data collection: EVOTION HA fitting pathway’ and ‘Equipment’ sections 
for details.
HA, hearing aid; HL, hearing loss; PTA, pure tone audiometry; QOL, quality of life; TTS, temporary threshold shift.
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 ► Otoscopy, tympanometry, acoustic reflexes.
 ► PTA if not already available.24
 ► The Glasgow Hearing Aid Benefit Profile (GHABP): 
Validated self-report instrument assessing listening 
difficulty, handicap, HA use and benefit across 
four everyday listening situations.26 The GHABP is 
routinely performed in the UK but not in Greece, 
where it will be performed as part of the study.
Additional research EVOTION assessments will be:
 ► The MoCA: Assesses visuospatial/executive function, 
naming, attention, language, abstraction, memory 
and orientation to time and place.27 28
 ► The Hospital Anxiety and Depression Scale (HADS): Four-
teen-item scale, seven of the items relate to anxiety 
and the other seven to depression.29 30
 ► The Health Utility Index Mark 3 (HUI3): Health status 
classification system assessing eight attributes: vision, 
hearing, speech, ambulation, dexterity, emotion, 
cognition and pain.31 It has demonstrated significant 
sensitivity to HL.32 A license has been obtained from 
the HUI organisation. It was translated into Greek 
by the first and second authors for the HUI organi-
sation according to the standard translation process 
founded on published guidelines for translation and 
cultural adaptation of HRQOL questionnaires.33
Visit 2: HA fitting
After their first visit EVOTION participants will be allo-
cated to an EVOTION HA fitting appointment including:
 ► Fitting of smart EVOTION HAs using the compres-
sion fitting rationale VAC+34 and OpenSound Navi-
gator.35 Also please see the ‘Equipment’ section.
 ► Verification of the HAs using real-ear measurements.
In addition to this, participants will be offered:
Figure 1 Flow diagram of the prospective data collection (part 2) of the study. See the ‘Prospective data collection: EVOTION 
HA fitting pathway’ section for details about the assessments. GHABP, Glasgow Hearing Aid Benefit Profile; HA, hearing aid; 
HADS, Hospital Anxiety and Depression Scale; HUI3, Health Utility Index Mark 3; MoCA, Montreal Cognitive Assessment; PTA, 
pure tone audiometry; REM, real-ear measurement. 
group.bmj.com on February 22, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
6 Dritsakis G, et al. BMJ Open 2018;8:e020978. doi:10.1136/bmjopen-2017-020978
Open Access 
 ► A mobile phone with an EVOTION application 
including:
 – A self-administered speech-in-noise test: This will be 
based on the Speech-in-Babble test36 37 that employs 
eight lists of monosyllabic phonemically balanced 
meaningful English words as the speech stimulus 
presented with multitalker babble as the masker.
 – An auditory training programme: This will be based 
on the Story in Noise, an auditory training pro-
gramme using words in phrases spoken by adult 
British female and male talkers.38 Phrases are tak-
en from a connected narrative taken from books 
aimed at foreign learners of English with a back-
ground of continuous steady-state speech-shaped 
noise. The listener is asked to click on one to three 
keyword(s) present in the target phrase from a set 
of two to six options, each incorrect answer being 
phonetically similar to the target. Corrective feed-
back is given. The phrase is replayed every time a 
wrong choice is made. Every auditory training ses-
sion lasts 15 min. Equivalent auditory training ma-
terial is under development in Greek.
 – A digit recall test: This measure of auditory working 
memory is based on the digit span subtest of the 
Wechsler Adult Intelligence Scale IV.39 Pairs of 
prerecorded spoken digit sequences will be played 
and the user will have to type in the sequences 
in the right or reverse order. On successful re-
call of at least one sequence from each pair, the 
sequence increases by one digit (maximum eight 
digits for forward and seven for backward recall). 
Discontinuation occurs when both sequences are 
recalled incorrectly.
 – A self-administered PTA: This will measure the 
pure tone threshold at 4 kHz where temporary 
threshold shifts are indicative of exposure to too 
loud sounds. The measurement follows Bekesy au-
diometry, where the intensity varies continuously 
and the user indicates whenever they can hear 
the tone by pressing and holding the on-screen 
button during the audible phase and releasing 
the button when they cannot hear the tone. The 
logged sound environment data then enables the 
mobile to calculate the actual level of the tone 
at the EVOTION HAs, and thus calibrate the 
measurement.
 – Other self-reported measures: These will include rat-
ings of HA benefit and self-reporting of noise ex-
posure that could lead to temporary or permanent 
threshold shift events.
 ► Biosensors integrated in a commercially available 
wristband: The biosensors collect physiological data 
associated with listening effort, that is, heart rate, 
respiratory rate and pulse.40 41
 ► Training on how to use the mobile application and 
biosensors.
For the 12 months following the time of fitting, contin-
uously data will be automatically collected via:
 ► The EVOTION HAs (audiological, behavioural, cogni-
tive and environmental data; see table 1 for details).
 ► The EVOTION mobile app (table 1).
 ► The biosensors (physiological data; table 1).
Visit 3: follow-up
At approximately 6–8 weeks postfitting, participants will 
be invited to attend a follow-up appointment including 
fine-tuning of HAs if required. Participants will also 
repeat the following assessments as in visit 1: the GHABP, 
the HUI3, the HADS and the MoCA.
Proposed sample size
This is a big data study and therefore traditional sample 
size calculations do not apply. The study will collect data 
to be fed in a public health policy decision support model, 
therefore the sample should be as large as possible. A 
recent big data study by Timmer et al20 used data from 
8500 HA users. In the present study, the total sample 
size of 1250 patients is the maximum number of patients 
that can be recruited based on available resources due 
to the requirements of the study, that is, continuous real-
world data collection and number of sources. Given the 
types of data and time points per patient, the expected 
data points for this sample exceeds 700 million. Even 
though the sample size is larger that of traditional clin-
ical trials with individuals with HL, there are no concerns 
with regards to enrolling a high number of patients in 
the study as this is an observational study with no substan-
tial harm expected for the participants (also see the ‘Data 
confidentiality’ section). The higher number relative to 
other studies can compensate for the possible variation 
in real-world data as opposed to lab-based data and for 
the risk of missing data due to the fact that data collec-
tion is partially in the hands of the participants. The high 
sample size allows broader inclusion criteria and there-
fore a wider coverage of degrees of HL.
Equipment
All participants will receive EVOTION HAs and mobile 
phones. Thirty per cent of participants will receive biosen-
sors, based on their ability and experience to use a wrist-
band and the availability of the devices. EVOTION HAs 
are manufactured by Oticon A/S. They are a research 
prototype (EVOTION-12) based on the CE marked 
and commercially available Oticon Opn. The physical, 
mechanical and electro-acoustic design of the EVOTION 
HAs are identical to the Opn HAs. However, the EVOTION 
HAs enable: (1) logging of HA use, volume changes, 
intentional and automatic programme shifts and sound 
environment measures and (2) adjustment to the volume 
and programmes via a paired Bluetooth connection and 
the mobile app. EVOTION HAs are suitable for people 
with mild to severe HL. The mobile phone used in the 
study is the Samsung Galaxy A3 (2017) and the wearable 
biosensor will be the Huawei Fit. Participants can keep 
their mobile phone and biosensor after the end of the 
12-month study period but will have to return these if they 
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withdraw during the study period. If any of the devices is 
damaged during the study, support or replacement will 
be offered. Participants can keep their EVOTION HAs 
after the end of the 12-month study period. However, if 
the devices are damaged beyond the end of the 24-month 
HA warranty period, it will not be possible to repair or 
replace these and participants in the UK will be offered 
standard NHS HAs.
data analysis
All data will be analysed using big data analytic tech-
niques.42 The focus will be on detecting patterns of (1) 
contextualised HA usage and effectiveness for different 
types of HL and (2) correlations between different 
factors and comorbidities affecting HL. Big data analytics 
will include statistics (eg, descriptive statistics, statistical 
testing and inference techniques) and data mining (eg, 
clustering and prediction), as the PHPDMs (see the ‘Intro-
duction’ section) require. The specification of analytic 
tasks in these models will define the input data sets, the 
exact analytic techniques and the form of outputs that 
the analysis will produce. An electronic record of these 
specifications will be held in the EVOTION platform and 
will be linked to the data used in the task, the outputs it 
produced and the member of the research team who initi-
ated the analysis and will also have access to its outcomes. 
This will ensure full transparency and auditability of all 
analytic tasks as well as the controlled and traceable access 
to the analysis outputs.
data handling and management
Data collected at the clinic may be initially entered in a 
paper or electronic case report form (CRF; only in the 
UK), in the respective local UK NHS patient system (as per 
routine care) or directly into a purpose-built electronic 
database, that will be part of the EVOTION platform. 
These data will then be transferred to the EVOTION data 
repository. Where available, hard copies of the CRFs will 
be held by the clinics who collected them. Data collected 
via the mobile phones will be automatically transmitted to 
the data repository. Access to these data will be provided 
only to approved members of the research team, based 
on an electronic access control system. Data collected by 
HAs and sensors will be transmitted to the mobile phone 
via Bluetooth connection and subsequently to the data 
repository. An internal Data Monitoring Committee 
will (1) decide regarding the retention of data in the 
EVOTION data repository after the end of the project 
and (2) establish rights to access the anonymised data in 
line with the UK and Greek research governance frame-
works as well as the General Data Protection Regulation.
data confidentiality
The member of the research team entering the data will 
be authenticated before the data entry starts. The system 
will be monitored for inactivity and will be automatically 
logged out, if detected to be inactive for a prespecified 
period of time, to ensure that no unauthorised person 
can get access to the EVOTION platform and data repos-
itory. Data will be transmitted in an anonymised form 
across all the communication lines between HAs, mobile 
phones and sensors, and the EVOTION platform itself. 
Device authentication and data integrity checks will also 
be in place. The transmission of data from the mobile 
phones to the EVOTION platform and data reposi-
tory will be encrypted to ensure the confidentiality and 
integrity of the transmitted data. The data will be stored 
in the EVOTION data repository in a fully anonymised 
form. The identity of the device(s) from which the data 
were obtained will be pseudoanonymised and will not 
be subjected to full de-identification as there might be 
circumstances where, following the analysis of data asso-
ciated with a particular device, clinicians might need to 
advise or alert the patients.
trial organisation and monitoring
The Chief Investigator of the study (D-EB) will ensure 
that the EVOTION research team conducts adequate 
monitoring activities, including adherence to the 
protocol, compliance with procedures for consenting 
and reporting adverse events and data quality. She or the 
principal investigator for each site will inform the sponsor 
should they have concerns that arise from monitoring or 
oversight procedures. In addition, and according to the 
Medical Research Council Guidelines for Good Clinical 
Practice (1998), a trial management group (TMG) and a 
trial steering committee (TSC) will also be convened. The 
TMG will be responsible for the day-to-day management 
of the trial and, as the study is not a formal clinical trial 
and is of low risk, will report directly to the TSC. The TSC 
will review and examine legal, ethical, data protection, 
privacy and security issues.
Patient and public involvement
The development of this protocol has been informed by 
stakeholder consultation with HA users, clinicians, poli-
cy-makers and the general public collected in another 
study within the EVOTION project. The study has also 
been discussed with and has received input by an external 
advisory board that was established for the needs of the 
project including people with HL and other professionals 
outside the EVOTION research team.
Ethics
Written informed consent will be taken by research 
personnel who have received Good Clinical Practice 
training (in the UK) or relevant education (in Greece). 
Participants will be entitled to withdraw from the study 
at any point without giving a reason. Data obtained up 
to the point of withdrawal will be analysed unless the 
participant requests it is withdrawn. This will not in any 
way affect their standard clinical care. In the case of with-
drawal participants will be asked to return the equip-
ment received during the study. Also see the ‘Equipment’ 
section.
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dissemination
The study will be presented in national and international 
events and conferences in Greece and the UK, will be 
published in scientific journals and will also be dissemi-
nated through newsletter articles, magazines and social 
media. Target audiences will include HA users, clinicians, 
policy-makers and the general public.
twitter #h2020evotion
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